单核细胞增生性李斯特菌作为肿瘤疫苗运送载体的研究进展

单核细胞增生性李斯特菌是一种兼性胞内寄生菌,能直接感染抗原递呈细胞,使所运送的外源抗原可以同时进入MHCⅠ类和MHCⅡ类抗原递呈途径,从而诱导强烈的CD⁺₈T细胞和CD⁺₄T细胞免疫应答。目前,减毒李斯特菌作为一种新型的活疫苗载体,在运送宫颈癌、黑色素瘤等肿瘤相关抗原方面业已取得较好的免疫保护效果,在抗肿瘤治疗中显示出诱人的前景。本文综述了单核细胞增生性李斯特菌的免疫应答特性及其作为治疗性肿瘤疫苗载体的相关研究进展。

Progress of Listeria monocytogenes as tumor vaccine vector

Listeria monocytogenes is a facultative intracellular bacterium that enters professional antigen presenting cells, presents passenger antigens to the major histocompatibility complex class I and II pathways, then elicits CD⁺₄ and CD⁺₈ T-cell-mediated immune responses. It was demonstrated that attenuated Listeria monocytogenes as a novel live vaccine vector in delivering tumor antigens of cervical cancer and melanoma etc., could induce strong protective immune response, and shows effective antitumor immunotherapeutics. This review discussed the characteristics of immune responses elicited by Listeria monocytogenes, and the progress of its antitumor immunotherapeutics as delivery vaccine vector.